This study aimed to verify the reliability of the 7 tissue differentially methylated regions used in the methylated DNA immunoprecipitation (MeDIP) real-time quantitative polymerase chain reaction (real-time qPCR) based approach of fetal DNA in maternal blood to diagnosis of fetal trisomy 21. Forty pregnant women with high risk pregnancy who were referred after first or second trimester screening tests, were selected randomly. For each sample whole DNA extraction (mother and fetus), fragmentation of DNA, immunoprecipitation of methylated DNA and real-time qPCR using 7 primer pairs was performed. D-value for each sample was calculated using the following formula D = -4.908+ 0.254 X EP1 + 0.409 X EP4 + 0.793 X EP5 + 0.324 X EP6 + 0.505 X EP7 + 0.508 X EP9 + 0.691 X EP12 . In all normal cases, D value was negative, while it was positive in all trisomy cases. Therefore, all normal and trisomy 21 cases were classified correctly which correspond to 100% specificity and 100% sensitivity for this method. The MeDIP real-time qPCR method has provided the opportunity for noninvasive prenatal diagnosis of fetal trisomy 21 to be potentially employed into the routine practice of diagnostic laboratories.
many other health problems (1, 2, 6, 7) . While most fetal aneuplordy leads to miscarriage, trisomy 21 has the maximum survival rate. Due to the highest survival rate, the prenatal detection of fetal trisomy 21 is one of the commonest reasons for referral of women for prenatal diagnosis (8, 9) . The incidence of births of children with DS rises with the age of the mother. Screening for DS is an important part of routine prenatal care. Prenatal diagnosis was presented in the 1970s with the major aim of detecting common aneuploidies such as trisomies 21, 18 and 13 (7, 10) . Screening tests like the first trimester combination test are nowadays accessible to all pregnant women. Risk calculation is based on maternal age, nuchal translucency (NT) measurement by sonography and two serum markers: free beta hCG (free β-hCG) and pregnancy-associated plasma protein-A (PAPP-A).
The test properties are rather good with a detection rate of almost 85-90% with a false-positive rate of 5-9% (9, 11) .
Following a positive prenatal screening test, women are usually recommended to perform fetal karyotyping, which is considered as the gold standard to confirm the presence or absence of aneuploidies. Despite that, the main problem of karyotyping is the long period of time needed to achieve definitive results. Other faster and cheaper methods which have been introduced include interphase FISH and QF-PCR, but their main disadvantage is that they do not provide a full graphic demonstration of all chromosomes (12) (13) (14) (15) .
Prenatal genetic diagnosis of DS and other
aneuploidies is done using common cytogenetic tests or DNA analysis which needs fetal DNA to be obtained by invasive methods such as chorionic villus sampling (CVS) during the first trimester and amniocentesis during the second trimester (16) (17) (18) .
Even so, all these methods are invasive and associated with risk of fetal loss (12, 19, 20) .
Therefore, developing a reliable technique for noninvasive prenatal diagnosis (NIPD) of fetal trisomy 21 is very important (8, 21, 22) .
Over the last few years, a great quantity of investigation have been accomplished on the development of noninvasive prenatal testing (NIPT) for fetal aneuploidies (23, 24) . The discovery of cell free fetal DNA (cffDNA) in the maternal circulation has opened up a new horizon in the field of prenatal care and screening. Detection of chromosomal aneuploidy is a challenging goal in NIPD research (22, (25) (26) (27) . Due to the high maternal DNA background and the nature of cffDNA in maternal plasma, determination of chromosomes dosage in the fetal genome is very difficult by common methods. To overcome these issues, background maternal DNA interference can be diminished by using molecular signatures present in maternal plasma but originating completely from fetus. The discovery of fetalspecific DNA methylation signatures in maternal blood offered an excellent opportunity to advent and improve new approaches for noninvasive screening testing. Genes that show differential DNA methylation between placental tissues and maternal blood cells have been used as fetal nucleic acid markers (20, (28) (29) (30) (31) . DNA methylation is a dynamic process and could change during development. It is believed that more than half of tissue differentially methylated regions (TDMRs) are methylated in embryonic tissues and during the differentiation, they undergo de-methylation process.These TDMRs have been used to enrich and assess fetal DNA ratio by using monoclonal antibody for methylated CpGs using MeDIP approach (16, 18, 32, 33) . (Table 1) and Table 1 . Primers used for real-time PCR (16) 
Region
Primer Name Sequence Amplicon size (bp)
Maxima SYBR Green/ ROX where X EPi is fraction value for each EP marker (33) .
Results
The ratio values obtained from the 7 selected DMRs (Table 2) showed that this approach could detect trisomy 21
cases with 100% specificity (19) . The results of our research are in line with those of previous studies and corroborate the high sensitivity and specificity This approach has provided the opportunity for NIPD of fetal trisomy 21 into many diagnostic laboratories (19, 35) . Although the present study is based on a small sample of participants and data from more samples will be of help, our results confirm that this technology could be effective for screening trisomy 21 in pregnant women and could be applied in clinical practice.
